MSB 3.21% $1.13 mesoblast limited

RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-202

  1. 15,643 Posts.
    lightbulb Created with Sketch. 5711
    Not sure the statistics agree with you on that .... especially given another 1,847 people died on Tuesday 4th Jan from COVID-19 in the USA alone ?


    The Doc the other day claimed that numbers were decreasing, which I disagreed with ...... compare the above post snippet with the below statistics for Tuesday 8th February 2022


    One month on from the original post and this substantial increase in COVID-19 daily deaths IMO would validate the need for the additional Remestemcel-L phase 3 trial for COVID-19 ARDS and sadly demonstrates that there would be ample available patients for recruitment ... That said, I am the first to admit that it needs to be funded by someone else like the NIH or the 'partner' SI eluded to in the Edison video presentation if that is not the NIH .....


    Just hurry up already .... these sorts of daily death numbers are unacceptable IMO


    https://www.worldometers.info/coronavirus/

    upload_2022-2-10_9-35-6.png
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.